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Abstract
Objective: We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated
risks and the factors involved in such risk acceptance.
Methods: From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We
obtained disease severity perception scores, personality traits’ scores, and risk-acceptance scores (RAS) so that
higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ
treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their
individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls.
Results: No differences between treatment groups were observed in disease severity perception and personality
traits. RAS were higher in NTZ than in DMD patients (p<0.01). Perception of the own disease as a more severe
condition tended to predict higher RAS (p=0.07). Higher neuroticism scores predicted higher RAS in the NTZ group
as a whole (p=0.04), and in high PML-risk subgroups (A-B) (p=0.02). In low PML-risk subgroups (C-E), higher RAS
were associated with a JCV+ status (p=0.01). Neither disability scores nor pre-treatment relapse rate predicted RAS
in either group.
Conclusions: Risk acceptance is a multifactorial phenomenon, which might be partly explained by an adaptive
process, in light of the higher risk acceptance amongst NTZ-treated patients and, especially, amongst those who are
JCV seropositive but still have low PML risk, but which seems also intimately related to personality traits.
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Introduction
Multiple sclerosis (MS), an inflammatory-demyelinating
disease of the central nervous system (CNS), is the second
most frequent cause of disability amongst young adults[1].
Over the last decade, an increasing number of new drugs have
been tried in patients with RRMS, with encouraging results,
showing greater efficacy than conventional first-line disease
modifying drugs (DMD)[2-12]. Some of these new molecules,
such as natalizumab (NTZ), fingolimod, and teriflunomide (in
the US), are already available on the market for patients with
RRMS[13], and some others will probably be available in the
near future. Therefore, drastic changes in the therapeutic
scenario are to be expected over the next few years, which
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may have an important impact on the natural history of the
disease. However, these highly effective drugs are likely to
entail some risk of potentially serious -although generally
infrequent- adverse events that patients will have to assume if
they want to benefit from them.
The efficacy of NTZ has been greatly demonstrated in the
setting of clinical trials[2-5] and day-to-day clinical practice[14].
However, its use has been limited by the risk of progressive
multifocal leukoencephalopathy (PML), an opportunistic
infection caused by the John Cunningham virus (JCV), which
may have fatal consequences in 20% of those affected, or lead
to serious disability in 40% of survivors[15]. PML risk is
associated to long NTZ treatment schemes, JCV seropositivity,
and a past history of immunosuppressant (IS) drug
treatment[15-18]. Up to now, more than 300 cases of PML
have been diagnosed worldwide[13]. At present, due to the
high efficacy of NTZ, numerous RRMS patients are reaching
the timepoint of two years of treatment and need to face the
decision whether to assume a higher PML risk or switch to
other second-line drugs, whose efficacy has not been
compared to NTZ, which could therefore mean a deterioration
of their disease. Apart from that, given that the other second-
line drugs can also entail a risk of secondary effects, it is likely
that, as time goes by, clinicians encounter an increasing
number of patients whose prognosis eventually depends on
their ability to assume treatment-associated risks. Thus, it is of
the highest importance to know the reasons that can lead to a
given patient to decide whether to continue on a given
treatment or not.
In 2012, we reported that amongst the NTZ-treated patients
who had the three PML risk factors, those with lower reductions
in disability scores while on treatment were more likely to
discontinue NTZ after a decision-making process[19]. We also
found that the neurologist with whom treatment discontinuation
had been discussed played a major role in the final decision.
Nonetheless, we did not study the involvement of other factors
such as personality traits or the perception of MS as a serious,
disabling disease.
The aim of the present study was to investigate the ability of
MS patients to accept risks associated to treatments, and the
factors involved in this risk acceptance. We focused on patients
who were already receiving NTZ, as a paradigm of second-line
treatment, and hypothesised that patients on NTZ, with an a
priori more severe disease than patients on first-line disease
modifying drugs (DMD), would be more prone to accept higher
risks than DMD patients. We also hypothesised that the
perception of MS as a more severe disease and the presence
of greater disability scores would make patients more prone to
accept higher risks associated to MS treatments.
Methods
Participants
From a total of 185 MS patients[20-22] who had received at
least one dose of NTZ in our centre, 141 were receiving this
drug by July 2011. Of them, four patients refused to participate,
one patient had a language barrier and we considered that his
inclusion was not appropriate, and 22 patients were not invited
for different reasons: pregnancy planning (five patients, all of
them had just stopped treatment), participation in another study
(five patients, who were about to start a clinical trial), and
agenda issues (12 patients). Therefore, a total of 114 patients
(81%) on NTZ treatment (that we called ‘NTZ group’) finally
participated in this study. They were not different from those
who did not participate (N=27), in terms of disease duration (t-
test: p=0.558), age (t-test: p=0.978), treatment duration (t-test:
p=0.259), and disability scores at NTZ onset (Mann-Whitney U
test: p=0.201). All NTZ-treated patients received NTZ in the
approved indication, that is, because they had suffered from
disabling relapses despite being on first-line DMD. However,
15 out of the 114 NTZ-treated patients who participated in this
study had an EDSS score at treatment onset greater than 5.5,
which is the maximum EDSS score allowed to receive NTZ in
our setting. In those cases, we had to ask for permission to the
competent authorities of our hospital to be able to offer NTZ to
these patients.
Besides, a group of 22 patients on first-line DMD was also
studied (‘DMD group’). They were consecutive patients who
attended the Day Hospital of our centre, either to start on first-
line DMD (10 patients) or to change from a first-line DMD to
another first-line DMD (12 patients).
Clinical and demographical characteristics
Age, gender, disease duration, Expanded Disability Status
Scale (EDSS)[23] scores at the time of the study, and the
annualised relapse rates (ARR) during the year before starting
on treatment, either on NTZ or first-line DMD, for the ‘NTZ
group’ or the ‘DMD group’, respectively, were recorded. All
relapses and EDSS scores over time were recorded using
patients’ files, which could be either physical (they contained
information up to 2009), or electronic (they contained
information after 2009). We also recorded, in the ‘NTZ group’,
variables associated with the individual risk of PML, such as
doses of NTZ received, presence of anti-JCV antibodies, and
past history of immunosuppression (IS). Thereafter, NTZ
patients were split into five subgroups, depending on their
individualised estimated PML risk: from A, with highest PML
risk, to E, with lowest PML risk, according to current knowledge
about natalizumab-associated PML as of July 2011[18] (Table
1).
Assessment of the perception of MS severity
For this purpose we used a survey containing visual analogic
scale (VAS) questions, whose possible values ranged from 0 to
10, as has been previously used[24]. Patients were asked to
answer to what extent they thought MS was a severe disease
(0 = MS is not at all a severe disease; 10 = MS is the most
severe disease you can think of), in general (i.e. for MS
patients as a whole) and in their particular case. We therefore
obtained two severity perception scores, i.e. a general and an
individual severity perception score, per patient.
Assessment of personality traits
For this purpose, the NEO Five-Factor Inventory of
personality traits was administered[25]. It explores five
personality traits, namely neuroticism, extroversion, openness,
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agreeableness, and responsibility, by means of 60 questions
(12 questions per personality trait) whose scores ranged from 0
to 4. Thereafter, averaged scores for each trait were obtained,
according to official guidelines[25].
Assessment of risk acceptance
Here, we presented five hypothetical therapeutic scenarios,
which had five different associated risks of a serious secondary
effect. Patients were asked to what extent they would like to
continue receiving a given drug if the associated annualised
risk of a serious secondary effect was 1/2,000,000 (very low
risk [therapeutic] scenario), 1/600,000 (low risk scenario),
1/5,000 (intermediate risk scenario), 1/100 (high risk scenario),
and 1/50 (very high risk scenario). Patients had to answer
these questions using visual analogic scales (VAS), whose
possible values ranged from 0 to 10 (0 = I would not like to
continue receiving this drug at all; 10 = I would like to continue
receiving this drug without any doubt). In order to help patients
to understand the risks associated to each therapeutic
scenario, we also presented five events totally unrelated to MS,
whose associated risks or likelihoods were similar to those
associated to the hypothetical therapeutic scenarios (Table
S1). Therefore, we obtained risk-acceptance scores (RAS),
one RAS for each therapeutic scenario, so that higher RAS
indicated better acceptance of risk.
Finally we averaged RAS for high and very high-risk
scenarios, thus obtaining a variable called ‘averaged RAS’,
which indicated the degree of acceptance of high and very high
treatment-associated risks.
Table 1. Distribution of NTZ-treated patients according to
individualised estimated PML risks.
PML risk
group
JCV
status
Number of
NTZ
infusions
Prior
IS
Estimated
PML riska
Estimated
PML riskb
Number
of
patients
A + > 24 + 8.1/1000(5.4–11.6)
11.1/1000
(8.3–14.5) 3
B + > 24 - 2.8/1000(2.0–3.8)
4.6/1000
(3.7–5.6) 32
C + < 24 + 1.2/1000(0.58–2.2)
1.6/1000
(0.91–2.6) 2
D + < 24 - 0.35/1000(0.19–0.60)
0.56/1000
(0.36–0.83) 17
E - < 24 or >24
+ or
-
<0.11/1000
(0–0.59)
<0.09/1000
(0–0.48) 60
A and B
(together) + > 24
+ or
- - - 35
C to E
(together) + or -
< 24 or >
24
+ or
- - - 79
This table shows the distribution of patients according to their estimated PML risk.
a: PML risks are expressed as mean (95% CI). according to the information
provided by Sandrock et al. (Sandrock et al. P03.248. AAN 2011); b: risks are
expressed as mean (95% CI). according to the information provided by Bloomgren
et al.. N Engl J Med 2012. Abbreviations: JCV: JC virus; IS: immunosuppression.
doi: 10.1371/journal.pone.0082796.t001
Statistical analysis
This study has a cross-sectional design.
To assess differences between treatment groups (‘NTZ
group’ and ‘DMD group’) in terms of clinical and demographical
characteristics, general and individual severity perception
scores, RAS and ‘averaged RAS’, we used t-tests, Mann-
Whitney U tests, or chi-square tests, depending on the variable
to be compared. To assess internal consistency of patients’
answers related to risk acceptance, paired t-tests were
performed to investigate differences between very-high- and
high-risk RAS, high- and medium-risk RAS, medium- and low-
risk RAS, low- and very-low risk RAS.
To investigate factors involved in risk acceptance, multiple
linear regression analyses were performed so that the
‘averaged RAS’ was taken as the dependent variable, and the
remaining variables, i.e. clinical and demographical data,
general and particular severity perception scores, and
personality traits’ scores were taken as independent variables.
In order to give information about the strength of the
association between the dependent and the independent
variables, correlation coefficients obtained within the multiple
regression analyses performed are also reported (when
statistically significant).
All analyses were performed with IBM® SPSS® Statistics
version 20. Statistical significance was considered whenever p
value was lower than 0.05. This study was approved by the
Ethics Committee of the Vall d’Hebron Research Institute and
by the Spanish Agency for Medicines and Health Products
(Agencia Española de Medicamentos y Productos Sanitarios
[AEMPS]). Participants provided their written informed consent
to participate in this study. Both Ethics Committees approved
this consent procedure.
Results
Clinical and demographical characteristics, disease
severity perception, and personality traits
Clinical and demographical characteristics are shown in
Table 2. As expected, NTZ patients had longer disease
durations (p<0.001), greater EDSS scores at the time of the
study (p<0.001), and higher ARR over the year before starting
on treatment (p=0.037) than DMD patients. No differences
were observed between treatment groups in terms of age,
gender distribution, or treatment duration.
As regards the PML risk factors amongst NTZ-treated
patients, 54 were JCV seropositive, and 60 JCV seronegative.
Amongst those JCV seropositive patients, 35 had received
more than 24 NTZ doses (> 2 years); amongst these, 3 had
also received mitoxantrone in the past (group A) and 32 had
not received any kind of IS (group B). The distribution of all
NTZ-treated patients according to their individualised estimated
PML risks is shown in Table 1.
In both treatment groups, patients considered that their own
disease was significantly less severe than was MS in general
(NTZ group: p<0.001; DMD group: p<0.001), but no significant
differences were observed between treatment groups in any of
the two severity perception scores (Table 2). Finally,
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personality traits were similar between both treatment groups
(Table 2).
Treatment-associated risk acceptance
NTZ patients showed significantly higher RAS than DMD
patients, for all five hypothetical therapeutic scenarios that we
presented (Table 3), indicating a higher acceptance of
treatment-associated risks. Furthermore, the higher the risk the
hypothetical therapeutic scenario had, the lower the RAS was
(Table 3).
Paired t-tests showed significant differences between very-
high- and high-risk RAS (p<0.001 [for NTZ group]; p=0.002 [for
DMD group]), high- and medium-risk RAS (p<0.001 [NTZ];
p=0.001 [DMD]), medium- and low-risk RAS (p<0.001 [NTZ];
p=0.008 [DMD]), and low- and very-low risk RAS (p=0.047
[NTZ]; p=0.002 [DMD]), indicating a good internal consistency
of patients’ answers.
Factors involved in risk acceptance
When all patients were investigated as a whole (NTZ and
DMD groups together), there was a trend towards a
relationship between higher ‘averaged RAS’ and higher
Table 2. Clinical and demographical characteristics,
disease severity perception scores, and personality traits.
 
NTZ group N =
114   
DMD group N =
22   p value
Clinical and demographical
characteristics    
Age (years)a 37.78 (8.12) 39.16 (11.11) 0.582c
Gender (males. %) 34 (30%) 6 (27%) 0.810d
Disease duration (years)a 12.92 (6.90) 5.21 (4.39) <0.001c
EDSS scoresb 3.75 (0-8) 2.00 (1-5) <0.001e
ARR (over the year before
starting on treatment)a 1.95 (0.95) 1.45 (1.05) 0.037
c
Treatment duration (years)a 2.55 (1.74) 2.45 (3.09) 0.889c
Disease severity perception
scores (range: 0-10)a    
In general 7.00 (1.97) 7.62 (1.75) 0.184c
In their particular case 5.77 (2.12)f 6.10 (1.79)f 0.507c
Personality traits scores
(range: 0-4)a    
Neuroticism 1.77 (0.73) 1.66 (0.65) 0.536c
Extroversion 2.42 (0.69) 2.44 (0.49) 0.881c
Openness 2.29 (0.60) 2.15 (0.46) 0.307c
Agreeableness 2.60 (0.50) 2.61 (0.41) 0.962c
Responsibility 2.65 (0.56) 2.59 (0.48) 0.612c
a: mean (standard deviation); b: median (range); c: independent samples t-test
(NTZ group vs. DMD group); d: Chi-square test (NTZ group vs. DMD group); e:
Mann-Whitney U test (NTZ group vs. DMD group); f: to compare disease severity
perception in their particular case vs. disease severity perception in general:
related samples t-test (NTZ group: p<0.001; DMD group: p<0.001). Abbreviations:
ARR: annualised relapse rate; DMD: disease modifying drugs; EDSS: expanded
disability status scale; NTZ: natalizumab.
doi: 10.1371/journal.pone.0082796.t002
disease severity perception scores in each particular case (i.e.
by the perception of having a more severe disease) (p=0.052).
Similarly, there was a trend towards a relationship between
higher ‘averaged RAS’ and higher neuroticism scores
(p=0.089), after correcting for treatment group (Table 4).
Table 3. Treatment-associated risk-acceptance scores.
 Risk-acceptance Scores (range: 0-10)a
Therapeutic scenarios-associated
risk   NTZ group DMD group p valueb
Very low (1(2.000.000) 8.85 (1.94) 7.50 (2.26) 0.019
Low (1/600.000) 8.49 (2.18) 6.32 (2.71) <0.001
Medium (1/5.000) 7.47 (2.75) 4.76 (3.07) <0.001
High (1/100) 4.29 (3.50) 2.43 (2.03) 0.002
Very high (1/50) 3.01 (3.36) 1.58 (1.83) 0.008
Average High and Very Highc 3.66 (3.35) 2.00 (1.86) 0.003
a: mean (standard deviation); b: independent samples t-test; c: averaged Risk-
Acceptance Scores for high and very high-risk scenarios (‘avRAS’).
doi: 10.1371/journal.pone.0082796.t003
Table 4. Factors involved in risk acceptance.
 Population studied
 
NTZ + DMD
(all patients)a
NTZ (A-E [all]
groups)
NTZ (A-B
groups)
NTZ (C-E
groups)
Predictive
variables     
Age and gender - - - -
Disease duration - - - -
EDSS - - - -
ARR - - - -
Positive JCV-
antibodies - - -
p=0.015;
CC=0.27
Prior IS - - - -
Disease severity
perception scores, in
general
- - - -
Disease severity
perception scores, in
their particular case
p=0.052;
CC=0.17 - - -
Personality traits
(neuroticism
scores)b
p=0.089;
CC=0.15
p=0.042;
CC=0.20
p=0.015;
CC=0.42 -
a: Multiple linear regression analyses are adjusted for treatment group, given the
strong association between treatment group and some clinical and demographical
variables; b: Neuroticism was the only personality trait that was associated with
risk acceptance; thus, higher neuroticism scores were related to higher risk
acceptance in those groups that are shown in the table. Abbreviations: ARR:
annualised relapse rate; CC: correlation coefficients obtained from the multiple
linear regression analyses performed; DMD: disease modifying drugs; EDSS:
Expanded Disability Status Scale scores; IS: immunosuppression; JCV: JC virus;
NTZ: natalizumab.
doi: 10.1371/journal.pone.0082796.t004
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When only NTZ-treated patients were investigated, only
higher neuroticism scores could predict higher ‘averaged RAS’
(p=0.042). When the same analyses were performed in
patients from groups A and B, i.e. higher PML-risk patients
(considered as a whole), again, only higher neuroticism scores
predicted higher ‘averaged RAS’ (p=0.015) (Table 4; Figure 1
(A)). Instead, when these analyses were performed in patients
from groups C to E, i.e. lower PML-risk patients (as a whole),
‘averaged RAS’ were only predicted by the fact of being JCV
seropositive (p=0.015). This is, patients who were JCV
seropositive had significantly higher ‘averaged RAS’ (Table 4;
Figure 1 (B)).
Discussion
Over the last years, the investigation into factors involved in
the decision-making process in patients with MS as regards
new therapeutic approaches has been gaining increasing
importance[24]. In fact, as new drugs are developed, it is
possible that the prognosis of a non-deniable number of
patients, especially those who have an early suboptimal
response to first-line DMD[26], depends on their ability to
assume risks associated to new treatments.
In this study, we aimed to investigate the ability of MS
patients to accept treatment-associated risks. In particular, we
focused on NTZ-treated patients, considering that NTZ is a
second-line drug and that these patients may have needed to
make a number of decisions as regards their treatments
throughout their lives. Despite the unequal numbers of patients
within each treatment group, we found that patients on NTZ
seemed to be more able to assume higher risks than patients
on first-line drugs. This, which was an expected result, also
indicates that our survey satisfactorily discriminated between
both groups, suggesting that patients’ answers probably
reflected patients’ genuine predisposition to accept risks.
However, we cannot say with this study whether the
differences between NTZ and DMD groups were the result of a
selection bias, i.e. since patients currently on NTZ were
originally more prone to assuming risks they finally started on
NTZ treatment, or whether they were the result of an adaptive
process. Namely, it would be possible that NTZ patients’ need
for starting on a second-line drug had made them more ‘open’
to assume higher risks. Along these lines, in a study where the
authors investigated to what extent MS patients on NTZ
treatment were willing to accept increasing hypothetical risks of
PML, they reported that patients were more prone to accept
higher PML risks than their physicians[24], suggesting that
patients on NTZ were more ‘prepared’ to assume higher risks.
However, as happened to us, they could not say whether this
higher predisposition had appeared before or after being on
NTZ treatment. Thus, only longitudinal studies that assess
patients’ attitudes towards risky therapeutic options over time
will finally tell us whether such possible adaptive process
actually exists.
We also aimed to investigate which factors were influencing
risk acceptance in both groups, but especially in the NTZ
group. Thus, when all patients were taken as a whole, the only
circumstances that marginally determined a higher risk
acceptance (apart from the fact of belonging to NTZ or DMD
groups) were the perception of the own MS as a more severe
disease, and higher neuroticism scores. Interestingly, when
only NTZ patients were investigated, the presence of more
evident neurotic traits emerged as the only variable significantly
associated with a greater predisposition to assume higher
risks. The same occurred when only higher PML risk patients
were investigated. Whereas it is understandable that a
Figure 1.  Main factors involved in risk acceptance among
NTZ-treated patients.  This figure shows the main factors
involved in risk acceptance among NTZ-treated patients. A.
This part shows the positive relationship between neuroticism
scores and risk acceptance for high- and very-high-risk
therapeutic scenarios among NTZ-treated patients from groups
A and B (higher PML risk groups) (p=0.015). B. This part
shows the relationship between JCV serological status and risk
acceptance among NTZ-treated patients from groups C-E
(lower PML risk groups): JCV seropositive patients accepted
significantly better high- and very-high-risk scenarios
(p=0.015).
doi: 10.1371/journal.pone.0082796.g001
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perception of their own MS as a more severe disease may
make people more avid to try new drugs, it was somehow
unexpected that the perception of MS, in general, as a more
severe disease did not have any influence in the amount of risk
patients wanted to assume. However, Heesen et al. similarly
found that a general perception of MS as a serious disease did
not determine the amount of risk the patients considered as
acceptable[24], although they did not look at the perception of
the disease at an individual level.
As regards the role of neurotic personality traits, it has been
reported that individuals showing higher neuroticism tend to be
more worried than others about their future[25]. Moreover, the
presence of high neuroticism scores in patients with MS has
been associated with higher levels of anxiety and
depression[27]. Taking this into consideration, it would have
been expected that more neurotic patients had been those
more frightened of secondary effects. Instead, we found that
those exhibiting more neuroticism were those more prone to
assuming higher risks, probably because they were more
worried for the disease than for the possibility of secondary
effects. This is in agreement with Taillefer et al., who found
that, in MS patients, the higher the neuroticism scores were,
the more concerned they were about their illness[28]. This
would also be in agreement with the finding, in our study, that
patients who perceived their own disease as a more severe
illness tended to accept higher risks.
When NTZ patients with lower PML risk were explored, the
only variable significantly associated with assuming greater
risks was the fact of being JCV seropositive. This is probably
the most enthralling result of our study and the best sign in
favour of the existence of an adaptive process towards
assuming higher risks: patients who knew that were positive,
even if they were still on the lower PML risk band, started to
assume higher risks earlier than patients who still were JCV
seronegative, maybe preparing themselves towards the near
future. Interestingly, this adaptive phenomenon would also
explain why NTZ patients accepted higher risks than DMD
patients in our study. Therefore, considering all these findings,
we suggest that risk acceptance is a multifactorial
phenomenon, which might be partly explained by this adaptive
process and is also intimately related to personality traits. Yet
further studies are needed to confirm this hypothesis.
Finally, it must be highlighted the absence of relationship
between EDSS scores or ARR and the ability to accept higher
risks. This was an unexpected result, since patients with a
more aggressive disease, namely patients with higher EDSS
scores and ARR, should have probably been more prone to
trying new, more risky therapies, if that meant that their
chances to slow down their disease activity were greater too.
Thus, this result reflexes the complexity of decision-making
processes and deserves further investigations.
Amongst the limitations of the present study there is the
cross-sectional design and the relatively low number of DMD-
treated patients, meaning that comparisons between treatment
groups should be taken with caution, although we were mainly
interested in the NTZ group rather than in the comparison
between treatment groups. In addition, our patients were not
assessed from a cognitive point of view, and the social and
educational status was not recorded. Therefore, it would be
debatable whether they fully understood the contents
presented within the survey or whether their brain pathways
involved in planning and decision-making were sufficiently
undamaged for us to measure their true ability to make
decisions. However, the high internal consistency of patients’
answers in terms of risk acceptance and the highly similar
personality traits’ scores between NTZ and DMD groups
suggest that patients’ understanding of the content of the
survey was correct. Nonetheless, future studies assessing the
impact of cognitive dysfunction on risk acceptance and the
decision-making process in general are warranted. Another
limitation could be the fact that our tool to assess risk
acceptance has not been validated yet. Given the lack of
standardised tests to assess this point, we designed our own
scale, which seems to have accurately measured such
treatment-associated risk acceptance, according to the
coherence of our results. Further research is nonetheless
needed to assess the validity of this test for other studies on
MS patients. Finally, we did not study our patients from the
imaging point of view and we did not therefore investigate the
role of brain damage in risk acceptance abilities. That is, we
cannot know whether the presence of a disconnection
syndrome secondary to damage in the main white matter
tracts[29] might have played a role in our results, as has been
suggested for other neuropsychiatric conditions[30].
In conclusion, this study suggests that patients on second-
line therapies such as NTZ would be more prone to accept
higher treatment-associated risks than other MS patients who
are on first-line drugs. This, together with the higher risk
acceptance amongst JCV seropositive NTZ patients, may
denote an adaptive psychological process. On the other hand,
the presence of certain personality traits may also determine
patients’ willingness to assume higher risks.
Supporting Information
Table S1.  In order to help patients to understand the
meaning of the therapeutic scenario-associated risks, we
also presented five scenarios totally unrelated to MS or MS
treatments with similar associated risks.
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